充血性心力衰竭 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week
Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine
Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure
Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)
Ejection Fraction Pros and Cons: JACC State-of-the-Art Review
Heart Failure With Preserved Ejection Fraction in the Young
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Clinical Trial

2020 Nov 11.

JOURNAL：Circulation.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

SD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al.

5913

Keywords: cardiorenal outcomes; empagliflozin

Full Text PDF